Altos Labs, a biotechnology firm known for cellular rejuvenation programming, has acquired Dorian Therapeutics, a senotherapeutics startup focused on neutralising senescent cells, according to the company.
The terms of the acquisition were not disclosed. Dorian, a Stanford University spin‑out, develops small‑molecule “senoblockers” designed to target cellular senescence—a process that can contribute to age‑related diseases by accumulating non‑dividing, dysfunctional cells.
Altos Labs said that Dorian’s platform operates by reactivating natural repair mechanisms via epigenetic regulation, modulating chromatin accessibility to restore youthful gene expression and tissue regeneration.
The companies’ technologies are seen as complementary, blending Altos’ cell reprogramming approach with Dorian’s senescent cell targeting. Dorian’s lead candidates have shown preclinical efficacy in models of lung fibrosis and osteoarthritis.
The acquisition expands Altos Labs’ strategy beyond in vivo reprogramming into senotherapeutics, reflecting a push toward therapies that address multiple ageing mechanisms.
Altos Labs claimed that integrating Dorian’s capabilities will accelerate the development of multi-pronged rejuvenation therapies, though it acknowledged that this remains early stage and human studies are still required.
